ArriVent bulks out ADC portfolio via $615M Alphamab deal
ADCIPO
ArriVent BioPharma teamed up with Jiangsu Alphamab Biopharmaceuticals on Wednesday to develop antibody-drug conjugates (ADCs) for cancer, the Pennsylvania-based biotech’s second deal focused on the modality.
Alphamab will use its linker-payload platform and glycan-conjugation technology to identify ADCs for ArriVent, who will have exclusive, ex-China development and commercialisation rights to the candidates. The Chinese biotech stands to receive $615.5 million, which comprises an upfront payment and potential milestones, in addition to tiered royalties.
The deal “strengthens and complements our pipeline with the potential to add multiple innovative new ADC programmes and exemplifies our strategic model of identifying and developing potential first-and best-in-class product candidates from across the globe,” said ArriVent CEO Bing Yao.
The agreement will help add fresh early-stage candidates to ArriVent’s pipeline, which consists mainly of EGFR inhibitorEGFR inhibitor firmonertinib. The oral small molecule is in three trials for various EGFR-mutated non-small-cell lung cancers.
ArriVent has one existing ADC deal, though details are scarce. The company is working with Aarvik Therapeutics to develop a therapy for solid tumours with improved activity and safety over single target bivalent ADCs, and a lead candidate is expected to be selected in late 2024 or early 2025.
The biotech made its public debut in January, raising $175 million in the year’s second IPO.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.